Please login to the form below
atherosclerosis
This page shows the latest atherosclerosis news and features for those working in and with pharma, biotech and healthcare.
Novartis’ Leqvio shows sustained efficacy and safety for cardiac patients
Atherosclerosis corresponds to the accumulation of lipids over time, mainly LDL-C in the inner lining of the arteries.
Latest news
-
Novartis bolsters anti-inflammatory R&D with $1.6bn IFM Tre buy
Heading the pack is IFM-2427, an NLRP3 antagonist that has just started a phase 1 clinical trial in healthy volunteers and has potential in chronic inflammatory disorders, including gout, atherosclerosis
-
Esperion craters as deaths mar atherosclerosis drug study
But the company insists its atherosclerosis candidate didn’t cause the deaths. ... Esperion has seen almost a fifth of the value wiped off its shares as a phase III trial of its atherosclerosis candidate bempedoic acid revealed a three-fold increase in
-
CV data sets up Novartis' Ilaris for blockbuster sales
with a prior heart attack and inflammatory atherosclerosis when added to standard therapy.
-
New outcomes data could unlock Repatha's potential, says Amgen
atherosclerosis compared to placebo.
-
Novartis boosts cardiovascular pipeline with $1bn Ionis deal
with underlying cardiovascular disease such as atherosclerosis. ... Atherosclerosis, commonly called the 'silent killer', is a major cause of death globally and no options exist today to effectively treat patients whose disease is driven by Lp(a) and
More from news
Approximately 3 fully matching, plus 51 partially matching documents found.
Latest Intelligence
-
Treatment and prevention of cardiovascular disease
While there is established and accumulating evidence that multiple strategies may delay the progression of atherosclerosis and reduce the incidence of ischaemic events, this comes with an added pill burden to
-
Lonafarnib: promising results in first-ever trial for progeria
The average lifespan of children with progeria is 13 (range 8–20) years, with death usually a consequence of heart attack or stroke caused by atherosclerosis.
-
Interview: Deepak Khanna, ABPI
In January 2003, he was promoted to vice president of the Atherosclerosis Franchise Business Group.
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest appointments
-
Milestone names chief medical officer
Dr Plat joins from Merck &Co where he was head of atherosclerosis and cardiovascular at the company's Merck Research Laboratories division.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
New insights into making behavioural change work
Lifestyle conditions, or noncommunicable diseases (NCDs), include obesity, type 2 diabetes mellitus, cardiovascular disease and atherosclerosis [1].
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- HCP ENGAGEMENT STUDY: Pharma shifts top priority to HCP insights and impact metrics
- AstraZeneca/Merck’s Lynparza combination recommended by NICE for advanced ovarian cancer
- BMS shares positive phase 3 results for Opdivo/Yervoy combination in colorectal cancer
- Stanford Medicine researchers find blood tests help predict organ failure
- GSK and GCOA report reveals global inequities in adult immunisation uptake
- A “Leaky Pipeline” and the Loss of Talented Female Physicians
No results were found
PMHub
fox&cat
Fox&cat is an award-winning healthcare communications agency which creates inspirational campaigns and programmes that exceed expectations. Priding itself on delivering...
Latest intelligence
- Clinical Trials Investigator and Patient Engagement Planning: A Customer Story
- ...
- New Playbook Alert: Virtual Patient Engagement
- ...
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
